Armodafinil
- Generic Name
- Armodafinil
- Brand Names
- Nuvigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 112111-43-0
- Unique Ingredient Identifier
- V63XWA605I
- Background
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patient...
- Indication
用于改善与阻塞性睡眠呼吸暂停（OSA）、发作性睡病或轮班工作障碍（SWD）相关的过度嗜睡的成年患者的清醒度。亦可用于治疗注意缺陷多动障碍、慢性疲劳综合征和重度抑郁症。
- Associated Conditions
- Narcolepsy, Shift-work related sleep disturbance, Somnolence
- Associated Therapies
- -
A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
- Conditions
- Interventions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT01317550
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 399
- Registration Number
- NCT01305408
- Locations
- 🇺🇸
Teva Investigational Site 225, Birmingham, Alabama, United States
🇺🇸Teva Investigational Site 295, Sherman Oaks, California, United States
🇺🇸Teva Investigational Site 122, Temecula, California, United States
Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
- Conditions
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT01256905
- Locations
- 🇺🇸
NYU Parkinsons and Movement Disorders Center, New York, New York, United States
Symptom Burden in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01219673
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01169753
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT01160380
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Michael J. Schlutz, M.D., Inc, Newport Beach, California, United States
🇺🇸James R. Berenson, MD, Inc., West Hollywood, California, United States
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 867
- Registration Number
- NCT01121536
- Locations
- 🇺🇸
Teva Investigational Site 411, Staten Island, New York, United States
🇺🇸Teva Investigational Site 105, Raleigh, North Carolina, United States
🇺🇸Teva Investigational Site 603, Watertown, Massachusetts, United States
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
- Conditions
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 135
- Registration Number
- NCT01096680
- Locations
- 🇺🇸
Clinilabs, Inc., New York, New York, United States
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 138
- Registration Number
- NCT01091974
- Locations
- 🇺🇸
University of Rochester James P. Wilmot Cancer Center, Rochester, New York, United States
🇺🇸Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 385
- Registration Number
- NCT01080807
- Locations
- 🇺🇸
Sleepmed Inc, Macon, Georgia, United States
🇺🇸Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Neurotrials Research Inc, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.